Global Markets for Generic Drugs

Published - Jan 2014| Analyst - Paul Evers| Code - PHM009G
Market Research Report Single User License: $2,750 Member Price: FREE

Report Highlights

The global generics sector reached $269.8 billion in 2012. This sector is expected to reach $300.9 billion in 2013 and $518.5 billion in 2018, with a compound annual growth rate (CAGR) of 11.5%.

Report Includes

  • An overview of the global market for generic drugs, including coverage of therapeutics such as antibacterials, antidepressants, anticancer agents, anti-arthritics, cardiovascular drugs (e.g., hypolipidaemics and antihypertensives), and drugs for respiratory conditions, including asthma and COPD.
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Examination of strategies employed by companies specializing in generics to meet the challenges of this highly competitive market, while also summarizing strategies employed by “originator” companies to forestall generic competition.
  • Discussion of important trends by product categories and major country markets, acknowledging that Brazil, China, India, Mexico, and Russia are among the rising markets for generic activity.
  • Comprehensive profiles of leading generics companies, and updates on mergers and acquisitions.

SCOPE OF REPORT

This report discusses the implications of all the above-mentioned trends, in the context of the current size and growth of the generics market, both in global terms and analyzed by the most important national markets. The nature and structure of the generics industry is discussed, with profiles of the leading 20-plus generics companies, and an update on mergers and acquisitions (M&A) activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of products involved.

ANALYST CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of two previous reports on the generics marketplace as well as analyses of major therapeutic categories and the pharmaceutical regulatory environment.

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Sep-2011| Analyst - Paul Evers| Code - PHM009F

Report Highlights

The global generics market is estimated at about $225 billion in 2011. By 2016, it is expected that the value of the total global generics sector will have risen to $358 billion, representing more than 18% of all pharmaceuticals, a projected compound annual growth rate (CAGR) of 9.7% between 2011 and 2016.

Published - Jul-2009| Analyst - Paul Evers| Code - PHM009E

Report Highlights

  • The global market for generic drugs was worth $81 billion in 2008, a figure that is expected to reach $84 billion in 2009. In 2014, the market is expected to amount to $168.7 billion, for a compound annual growth rate (CAGR) of 15% in the 5-year period.
  • Sales of U.S. generic drugs currently dominate the market, estimated at $33 billion in 2009 and projected to increase at a CAGR of 10.4% to $54 billion in 2014.
  • Japan’s generic drugs market is expected to have the highest rate of growth among major markets at 12.2%, increasing from $5.4 billion in 2009 to $9.6 billion in 2014.
Published - Aug-2002| Analyst - Lynn Gray| Code - PHM009D

Report Highlights

  • The U.S. prescription generic drug market is projected to grow from an estimated $11.1 billion in 2001 to more than $19 billion in 2006, representing an average annual growth rate (AAGR) of 11.4%.
  • Major growth in the market is projected to derive from the respiratory, central nervous system, gastrointestinal and anticancer therapeutic categories.
  • Cardiovascular drugs alone represent nearly 21% of the generic prescription drug market.
  • Anti-infectives (14.4%) and antiarthritics/analgesics (14.0%) are the next largest generic drug categories.

Want to Customize this Report?

Contact us for a confidential discussion.

781-205-2433

Custom Report
RELATED REPORTS
Share This Report